QuidelOrtho CFO awarded 29,444 RSUs

QuidelOrtho Corporation reported an equity compensation grant to its Chief Financial Officer, Joseph M. Busky.

Accepted by SEC EDGAR 02/03/2026 - 07:49 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

QuidelOrtho Corporation reported an equity compensation grant to its Chief Financial Officer, Joseph M. Busky. On January 30, 2026, he was awarded 29,444 restricted stock units (RSUs), each representing one share of QuidelOrtho common stock, at a grant price of $0 as part of his compensation.

According to the vesting schedule, 9,814 shares will vest on January 30, 2027. The remaining 19,630 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning Busky’s incentives with the company’s multi‑year performance.

Insider Trade Summary

Grant/Award: 29,444 shares

Grant/Award 1 txn

Insider Busky Joseph M.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	29,444	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 29,444 contracts (Direct)

Holdings Before and After: Restricted Stock Units, 0 to 29,444 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation Common Stock.
2. F2. 9,814 shares will vest on January 30, 2027; the remaining 19,630 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did QuidelOrtho (QDEL) report for Joseph M. Busky?

QuidelOrtho reported that Chief Financial Officer Joseph M. Busky received 29,444 restricted stock units on January 30, 2026. These RSUs are equity compensation, giving him the right to receive the same number of QuidelOrtho common shares as they vest over time.

How many QuidelOrtho (QDEL) restricted stock units were granted to the CFO?

Joseph M. Busky was granted 29,444 restricted stock units. Each unit represents the right to receive one share of QuidelOrtho common stock, providing long-term equity-based compensation that links his potential future ownership directly to the company’s share performance.

What is the vesting schedule for Joseph M. Busky’s QuidelOrtho (QDEL) RSUs?

The RSUs vest in three steps: 9,814 shares vest on January 30, 2027, and the remaining 19,630 shares vest in equal installments on January 30, 2028 and January 30, 2029. This multi-year schedule supports long-term alignment with shareholders.

Did Joseph M. Busky pay anything for the QuidelOrtho (QDEL) RSUs?

No, the Form 4 shows a price per unit of $0 for the 29,444 restricted stock units. This indicates they were granted as compensation, not purchased in the open market, which is typical for executive equity awards in public companies.

How many derivative securities does the QuidelOrtho (QDEL) CFO hold after this grant?

Following the January 30, 2026 transaction, Joseph M. Busky beneficially owns 29,444 restricted stock units directly. These units correspond to an equal number of potential QuidelOrtho common shares, subject to the stated vesting dates and continued service conditions.

Is Joseph M. Busky’s QuidelOrtho (QDEL) RSU award reported as a direct or indirect holding?

The Form 4 classifies the 29,444 restricted stock units as held with direct ownership. There is no indication of an intermediary entity or trust in the ownership field, so the award is attributed directly to the Chief Financial Officer personally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busky Joseph M.

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/30/2026		A		29,444		(2)	(2)	Common Stock	29,444	$0	29,444	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation Common Stock.

2. 9,814 shares will vest on January 30, 2027; the remaining 19,630 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

Remarks:

	/s/ Phillip S. Askim, attorney-in-fact for Joseph M. Busky	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.